透過您的圖書館登入
IP:3.15.221.146
  • 學位論文

放射性碘標誌胸腺嘧啶鹼基化合物[123I]IaraU作為基因探針之研究

Evaluation of 123I-labeled 2'-hydroxy-2'-deoxy-1-β-D-arabino-furanosyl-5-iodouracil ([123I]IaraU) as a gene probe

指導教授 : 羅建苗

摘要


本實驗的目的在於發展新的基因探針。在研究中測試放射性標誌嘧啶核苷的類似物(123I-labeled 2’-hydroxy-2’-deoxy-1-β-D- arabino-furanosyl-5-iodouracil ([123I]IaraU),作為觀察HSV1-sr39tk基因表現的造影劑之可能性。實驗方法:利用老鼠的攝護腺癌細胞(Tramp-C1),同時轉殖突變型自殺基因(HSV1-sr39tk)及細胞間素-3(IL-3),在活體外試驗,以經轉殖的細胞Tramp-C1/IL3-tk為實驗組,野生型Tramp-C1為對照組,測量細胞吸收[123I]IaraU的情形。在活體內試驗,以Tramp-C1/IL3-tk及Tramp-C1細胞分別種植於近交系小鼠的皮下,待形成腫瘤後,將[123I]IaraU注入體內,ㄧ則以犧牲動物方式求取體內器官組織的分布,另ㄧ則藉由動物用微型單光子/電腦斷層融合影像儀(microSpect/CT)觀察[123I]IaraU在老鼠體內的分布情形。實驗結果:以Tramp-C1/IL3-tk及Tramp-C1細胞測試細胞毒殺濃度(CC50),發現[123I]IaraU對於tk基因轉殖之細胞不具有專一性,Tramp-C1/IL3-tk及Tramp-C1的CC50之值相近,分別為363.9μM及 309.7μM。注入8小時後的細胞吸收測試,得到Tramp-C1/IL3-tk細胞吸收稍略大於Tramp-C1細胞,並得知[123I]IaraU停留在細胞質而未進入細胞核。[123I]IaraU注入植有腫瘤之老鼠所得到生物分布結果在6小時胃腸道有大量吸收,24小時後從體內代謝,所得到之microSpect/CT影像,於注射後一小時略有滯留tk轉殖腫瘤的影像,同時在胃腸道有大量吸收的情形。結論:由本實驗得知,[123I]IaraU需進一步詳細測試以確認作為觀察HSV1-sr39tk基因系統表現的基因探針之可能性。

並列摘要


Evaluating a new probe for monitoring gene expression for the gene therapy efficacy was dealt with in the study. The radiolabeled nucleoside analogue, 5-123I-iodo-2’-hydroxy-2’- deoxy-1-β-D- arabinofuranosyl-uracil ([123I]IaraU), was proposed to be a substrate for imag-ing HSV1-tk expression. Methods: The rat prostate cancer cell line Tramp-C1 was trans-duced with HSV1-sr39tk and IL-3. The transduced Tramp referred as Tramp-C1/IL3-tk to-gether with the Tramp-C1 as a control was employed for the test of in vitro uptake of [123I]IaraU. Tramp-C1/IL3-tk cells as well as the Tramp-C1 cells were subcutaneously inocu-lated to produce the xenografts in C57BL/6J mice. Biodistribution study was carried out for the animals after being [123I]IaraU injected for 6h and 24h. The animals were microSpect/CT imaged after 1h postinjection. Results: The cytotoxicity of IaraU was surveyed on Tramp-C1/IL3-tk and Tramp-C1. There was no significant difference between the tk trans-duced and the wild-type cells. The CC50 of IaraU was 309.7μM for Tramp-IL3-tk and 363.9μM for Tramp-C1. The cell uptake for Tramp-C1/IL3-tk by [123I]IaraU was slightly greater than Tramp-C1 after incubation for 8 h. The cell internalization test showed that Tramp-C1/IL3-tk cells trapped [123I]IaraU in the cytoplasm. For in vivo trial, Tramp-C1/IL3-tk and Tramp-C1 were inoculated subcutaneously into the left and right flank of C57BL/6J mice separately. After the xenograft was generated, [123I]IaraU was injected via tail vein for biodistribution study and microSpect/CT imaging. The biodistribution results showed that GI tract retention at 6h, and metabolized from the body at 24h. The imaging showed early (1h) ambiguous localization of [123I]IaraU in Tramp-C1/IL3-tk xenograft, and no accumulation in the Tramp-C1 xenograft. Simultaneously, the image showed significant and apparent retention of [123I]IaraU in GI tract. Conclusion: [123I]IaraU has not sufficiently evidenced as an efficacious gene probe for monitoring the gene expression in the HSV1-sr39tk system from the study.

並列關鍵字

HSV1-sr39tk 123I microSpect/CT Tramp-C1

參考文獻


6. R. G. Blasberg and J. G. G. Tjuvajev, Molecular nuclear medicine, Springer, 2003.
12. J. G. Tjuvajev, G. Stockhammer, R. Desai, H. Uehara, K. Watanabe, B. Gans-bacher and R. G. Blasberg, Imaging the expression of transfected genes in vivo, Cancer Res 55 (1995), no. 24, 6126-6132.
1. B. Degreve, G. Andrei, M. Izquierdo, J. Piette, K. Morin, E. E. Knaus, L. I. Wiebe, I. Basrah, R. T. Walker, E. De Clercq and J. Balzarini, Varicella-zoster virus thymidine kinase gene and antiherpetic pyrimidine nucleoside analogues in a combined gene/chemotherapy treatment for cancer, Gene Ther 4 (1997), no. 10, 1107-1114.
2. C. Grignet-Debrus, V. Cool, N. Baudson, B. Degreve, J. Balzarini, L. De Leval, S. Debrus, T. Velu and C. M. Calberg-Bacq, Comparative in vitro and in vivo cytotoxic activity of (e)-5-(2-bromovinyl)-2'-deoxyuridine (bvdu) and its ara-binosyl derivative, (e)-5-(2-bromovinyl)-1-beta-d-arabinofuranosyluracil (bvarau), against tumor cells expressing either the varicella zoster or the her-pes simplex virus thymidine kinase, Cancer Gene Ther 7 (2000), no. 2, 215-223.
4. K. W. Culver, Z. Ram, S. Wallbridge, H. Ishii, E. H. Oldfield and R. M. Blaese, In vivo gene transfer with retroviral vector-producer cells for treatment of ex-perimental brain tumors, Science 256 (1992), no. 5063, 1550-1552.

延伸閱讀